217 related articles for article (PubMed ID: 29573142)
1. Development of an unbiased, semi-automated approach for classifying plasma cell immunophenotype following multicolor flow cytometry of bone marrow aspirates.
Post SR; Post GR; Nikolic D; Owens R; Insuasti-Beltran G
Cytometry B Clin Cytom; 2018 Sep; 94(5):602-610. PubMed ID: 29573142
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
3. Utility of nine-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: a comparison with bone marrow morphologic findings and concurrent M-protein studies in serum and urine.
Behdad A; Ross CW; Jacques J; Kota U; Keren D; Stoolman L
Am J Clin Pathol; 2014 Sep; 142(3):398-410. PubMed ID: 25125632
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of minimal residual disease in multiple myeloma patients detected by 8-color panels and next generation flow cytometry].
Wang XF; Wang TT; Zhang ZY; Zhou HX; Zhang YR; Chen WM; Geng CY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):512-517. PubMed ID: 31340626
[No Abstract] [Full Text] [Related]
5. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.
Peceliunas V; Janiulioniene A; Matuzeviciene R; Griskevicius L
Cytometry B Clin Cytom; 2011 Sep; 80(5):318-23. PubMed ID: 21634008
[TBL] [Abstract][Full Text] [Related]
6. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
[TBL] [Abstract][Full Text] [Related]
7. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
[TBL] [Abstract][Full Text] [Related]
8. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
[TBL] [Abstract][Full Text] [Related]
9. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study.
Limvorapitak W; Srisum-Ang T; Chimres C; Warnnissorn N; Kanitsap N
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e27-37. PubMed ID: 26796980
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
[TBL] [Abstract][Full Text] [Related]
12. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
[TBL] [Abstract][Full Text] [Related]
13. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].
Wang YZ; Lu J; Hao L; Chang Y; He LL; Huang XJ; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):272-278. PubMed ID: 28468086
[No Abstract] [Full Text] [Related]
14. Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry.
Schouweiler KE; Karandikar NJ; Holman CJ
Cytometry B Clin Cytom; 2019 Jul; 96(4):310-318. PubMed ID: 31140731
[TBL] [Abstract][Full Text] [Related]
15. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
[TBL] [Abstract][Full Text] [Related]
17. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
van Velzen JF; van den Blink D; Bloem AC
Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
[TBL] [Abstract][Full Text] [Related]
18. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
Lisenko K; Schönland S; Hegenbart U; Wallenwein K; Braun U; Mai EK; Hillengass J; Goldschmidt H; Jauch A; Ho AD; Raab M; Hundemer M
Cytometry B Clin Cytom; 2017 Mar; 92(2):145-152. PubMed ID: 26666746
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
20. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
